Cite
HARVARD Citation
Hingorani, S. et al. (n.d.). 2321 High response rate and progression free survival with PEGylated recombinant human hyaluronidase added to Nab-Paclitaxel/ Gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized Phase 2 study. European journal of cancer. pp. S439-S440. [Online].